X-LINKED SEVERE COMBINED IMMUNODEFICIENCY (XSCID)

Clinical trials for X-LINKED SEVERE COMBINED IMMUNODEFICIENCY (XSCID) explained in plain language.

Never miss a new study

Get alerted when new X-LINKED SEVERE COMBINED IMMUNODEFICIENCY (XSCID) trials appear

Sign up with your email to follow new studies for X-LINKED SEVERE COMBINED IMMUNODEFICIENCY (XSCID), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New gene therapy offers hope for 'Bubble Boy' disease patients who failed transplants

Disease control Recruiting now

This trial is testing a new gene therapy for patients aged 2 to 50 with X-linked Severe Combined Immunodeficiency (XSCID), a severe genetic immune disorder. The treatment aims to correct the faulty gene in a patient's own blood stem cells and infuse them back after mild chemother…

Matched conditions: X-LINKED SEVERE COMBINED IMMUNODEFICIENCY (XSCID)

Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control

Last updated Mar 30, 2026 14:35 UTC

X-LINKED SEVERE COMBINED IMMUNODEFICIENCY (XSCID)

Get alerted when new X-LINKED SEVERE COMBINED IMMUNODEFICIENCY (XSCID) trials appear

New gene therapy offers hope for 'Bubble Boy' disease patients who failed transplants